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Abstract: Nitric oxide (NO) is naturally synthesized in the human body and presents many beneficial
biological effects; in particular on the cardiovascular system. Recently; many researchers tried to
develop external sources to increase the NO level in the body; for example by using amidoximes
and oximes which can be oxidized in vivo and release NO. In this review; the classical methods
and most recent advances for the synthesis of both amidoximes and oximes are presented first.
The isomers of amidoximes and oximes and their stabilities will also be described; (Z)-amidoximes
and (Z)-oximes being usually the most energetically favorable isomers. This manuscript details also
the biomimetic and biological pathways involved in the oxidation of amidoximes and oximes. The key
role played by cytochrome P450 or other dihydronicotinamide-adenine dinucleotide phosphate
(NADPH)-dependent reductase pathways is demonstrated. Finally, amidoximes and oximes exhibit
important effects on the relaxation of both aortic and tracheal rings alongside with other effects as the
decrease of the arterial pressure and of the thrombi formation
Keywords: amidoxime; oxime; synthesis; isomerism; nitric oxide; oxidation
1. Introduction
In recent years, oximes and amidoximes (oximes in which one of the substituents is an amino
group) (Figure 1) have gained high interest. These compounds are usually easy to synthesize and
were studied in many different fields such as coordination [1] or materials chemistry [2,3] but also for
their numerous biological activities. Moreover, the amidoxime function is often used as bioisoster of a
carboxylic acid, and there are some successful examples of drug candidates exhibiting cardiotonic or
antiarthritic properties containing the amidoxime moiety.
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Oximes and amidoximes have also gained high interest regarding their ability to release nitric 
oxide (NO). The oxidation of these compounds can be catalyzed by various hemoproteins like 
cytochrome P450 (CYP450) or horseradish peroxidase (HRP) [4]. The first step of arginine oxidation 
Figure 1. Structures of amidoximes and oximes.
Oximes and amidoximes have also gained high interest regarding their ability to release nitric
oxide (NO). The oxidation of these compounds can be catalyzed by various hemoproteins like
cytochrome P450 (CYP450) or horseradish peroxidase (HRP) [4]. The first step of arginine oxidation
, , 2470; doi:10.3390/molecules24132470 www. dpi.co /j r l/ l l
Molecules 2019, 24, 2470 2 of 19
has been extensively studied since the intermediate product, N-hydroxy-l-arginine (NOHA) exhibiting
an amidoxime function, is oxidized by NO-synthase (NOS) and other enzymes like CYP450 into
NO (Figure 2) [5]. NO is involved in many physiological processes such as neurotransmission,
blood pressure regulation, or immunomodulation. Thus, it is important to have external sources of
NO specially when NOS presents an abnormal activity as it is the case for patients having diseases like
diabetes or hypertension [6,7]. For this reason, exogenous compounds able to be oxidized by different
pathways that do not involve NOS are of high interest.
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Microsomal oxidation of amidoximes generates the corresponding amides and/or nitriles. It has
been demonstrated that these oxidative cleavages of C=N bonds to the corresponding C=O bonds result
in a transfer of one oxygen atom (dependent on CYP450) from O2 to the substrate, with simultaneous
release of NO [8].
In 1986, a patent was deposited for a series of compounds containing an amidoxime function
possessing cardiotonic activities and allowing an increase in the heart muscle force [9]. In 1989,
a second patent proved that many compounds bearing amidoxime functions can reduce heart failures
by increasing the contractile force of the heart muscle [10]. These studies were followed by the work
of Shahid et al. who demonstrated that once the cardiotonic agent depicted in Figure 3 injected in
isolated cardiac and vascular tissues, positive chronotropic and inotropic effects were observed [11].
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The oxidations of oximes and amidoximes were studied in vitro using either chemical reagents like
2-iodobenzoic acid (IBX) or IBX associated to tetraethylammonium bromide (TEAB) [12] or biological
ones like microsomes of rats containing CYP450 [5]. Amidoximes are also known to be reduced
in vivo into amidines exhibiting important anti-microbial activities against many pathogens such as
pneumocystis and protozoan [13,14].
In this review, we focus on the oxidation methods of both amidoximes and oximes developed
over the last twenty years, topic that has never been described to date. The first part is devoted to the
structure and isomerism of these compounds, which is an important subject only scarcely presented in
the literature. Next, the major methods developed for the synthesis of amidoximes and oximes will be
reported. Finally, the last part will describe the in vitro oxidation steps of amidoximes and oximes via
chemical as well as biological processes. The oxidation mechanisms will also be presented in order to
describe the exact pathways of NO release. Finally, the last part will focus on the in vivo oxidations of
amidoximes and oximes in rats and rabbits alongside with their effects like the release of NO, the blood
pressure regulation and the vasodilatation.
2. Isomerism of Amidoximes and Oximes
Amidoximes and oximes have poorly been studied in the literature regarding their isomerism.
However, this topic is of high interest for the determination of their structure. These two compounds
can exhibit two types of isomers, (i) geometrical diastereoisomers Z or E, and (ii) constitutional isomers
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(tautomers). Better knowledge of the relative stability of the tautomeric forms of amidoximes would
permit to elucidate some aspects of their pharmacological activity, of their reactivity and of their ability
to coordinate with metal centers.
Some studies were devoted to amidoximes in order to clarify their structure. Four main amidoxime
tautomers plus their geometrical isomers (Z/E) were studied, namely amidoxime, iminohydroxylamine,
aminonitrone and nitroso-amine (Figure 4) [15,16]. In 1964, the presence of a zwitterionic form for
amidoximes was demonstrated. This zwitterion or aminonitrone was identified via FT-IR by the
presence of a medium to strong band at 1690 cm−1 associated to the amidoxime C=N stretching at
1656 cm−1. The main aminonitrone and amidoxime IR bands are summarized in Table 1 [17].
Table 1. Infrared bands in solid and liquid phases of amidoximes.
Functions Stretching Solid Phase (cm−1) Stretching Liquid Phase a (cm−1)
Amidoxime form
OH - 3620
NH2 3400 and 3500 (sh)
NH2 scissor 1575–1620
Associated OH and NH2 2500 and 3300 (br)
C=N 1650–1670 (vs)
Aminonitrone form C=N+(H) 1690 (m – s) -
a liquid phase stretching is performed in chloroform; sh: sharp, br: broad, vs: very sharp, m: medium, s: strong.
Recent theoretical and experimental studies show that the most stable and dominant form is the
Z-amidoxime [15,16,18]. This isomer is more stable than the iminohydroxylamine, the aminonitrone
and the nitroso-amine, the latter being the less stable [18]. However, according to the most recent
published work on that topic [16], three amidoximes isomers may coexist due to their close relative
energies: the Z-amidoxime as the most stable form in both protic and aprotic solvents with the
Z-aminonitrone and the E-amino oxime as the minor forms. These theoretical studies were conducted
on two compounds, benzamidoxime and acetamidoxime. Z-aminotrone and E-amidoxime are the most
energetically stable after the dominant form Z-amidoxime: for acetamidoxime, the relative energies
of these two tautomers are of 3.0 kcal/mol and 3.5 kcal/mol, respectively, while for benzamidoxime
they are of 4.5 kcal/mol and 5.4 kcal/mol, respectively. The other tautomers, E-aminonitrone and all
iminohydroxylamine isomers are less energetically favorable since their relative energies were higher
than 8.5 kcal/mol in the case of acetoxime and of 9.8 kcal/mol for benzamidoxime. The nitroso-amine is
always the less energetically stable isomer (∆G ≈ 30 kcal/mol). The other tautomers show stabilities in
between the tautomers mentioned above, the iminohydroxylamine exhibiting an intermediate stability
with ∆G ≈ 10–13 kcal/mol (Figure 4) [16,18].
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Oximes tautomers were also studied and three main tautomeric forms were identified, the oxime,
the nitrone and the nitroso compound (Figure 5) [19,20]. Depending on the structure, other cyclic
tautomers may also exist [19]. These various isomers may present different biological activities [20] but
no data can be found in the literature. The first identified isomerization was the oxime–nitrone [21].
Even if both nitrone and nitroso tautomers were identified to be less stable than the oxime form [22],
the nitrone form exhibits a higher reactivity than the oxime, especially in cyclooaddition reactions and
nucleophilic addition to unsaturated electrophiles [16,23]. The presence of an electron donating group
on the oxime moiety allows to decrease the energy gap between the oxime and the nitrone form and
stabilizes this latter, which facilitates addition reactions [16]. However, the oxime form is more reactive
than the nitrone at high pH [24].
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The oxime–nitrone tautomerism is the mostly studied in the literature and its mechanism was
investigated. Rec ntly, Lopez et al. demonstrated by theoretical calculations that this isomerizatio
occurs via a bimolecular mechanism involving two oximes or two nitrones [23]. Previous studies
suggested that the oxime–nitrone tautomerism likely originated from a thermal 1,2-hydrogen shift and
a solvation effect [25–28].
Oximes can also exist as stereoisomers (Z/E forms). Numerous studies showed that the (Z)-oxime
is the most stable configuration. This was proven by differential scanning calorimetry (DSC) studies in
which heating and melting of the E- xime afforded the Z-oxime. The oxime in its (E) c nfiguration
may be present with the Z-oxime but it represents the minor specie [20,25].
3. Synthesis of Oximes and Amidoximes
According to the literature, amidoximes and oximes are compounds easily synthesized in high
yields. Amidoximes are usually prepared from the corresponding nitriles and hydroxylamine while
oximes are generated from the aldehydes/ketones and hydroxylamine.
3.1. Synthesis of Amidoximes
Amidoximes are compounds possessing an amino and a hydroxymino function on the same
carbon (Figure 1) [7]. The first synthesized amidoxime is formamidoxime obtained in 1873 by
Lossen and Schigerdecker [29,30] but the first chemical structure of amidoximes only appeared in
1884 with Tiemann’s work [30,31]. Many synthesis methods of amidoximes were explored but the
most commonly used nowadays is the nucleophilic attack of hydroxylamine on a nitrile (vide infra).
Tables 2–4 summarize all the processes developed for amidoximes synthesis and reactions are classified
by the type of additives used [7,30]. The methods de cribed in Tables 3 and 4 are scarcely used
nowadays because they require more sophisticated procedures.
Table 2 shows that amidoximes can be prepared from hydroxylamine and nitrile, thioamide,
amidine hydrochloride, hydrazide imide, iminoether, imidoylbenzotriazole, and pyrazine derivatives.
The attack of hydroxylamine on nitriles is the mostly used method since Tiemann showed that mixing a
nitrile with hydroxylamine hydrochloride and sodium carbonate in an alcohol produces the corresponding
amidox me after s veral hours of heating at 60–80 ◦C [31]. Via this method, amidoximes are gen rally
prepared in high yield, up to 98% (entry 1) [32]. Synthetic methods described in entries 2 and 3
are more scarcely used since the starting compounds are prepared from nitriles [30]. In some cases,
better results are obtained using thioamides than the nitriles [33]. The reaction of hydroxylamine
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with thioamides [30,33,34], amidines, hydrazide imides [30] or iminoethers [35], even if rarely used,
usually affords the targeted amidoximes in yields varying from 60% to 100% (entries 2–4).
Table 2. Amidoxime syntheses using hydroxylamine.
Entry Hydroxylamine Action on Reaction
1 nitrile
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The second synthetic process allowing the preparation of amidoximes involves the reaction of 
ammonia or amines with oximinoethers, hydroximic acids or nitric oxides (Table 3) [7,30]. The first 
example described in the literature is the reaction of ammonia with ethyl benzhydroximic acid for 8 
h at 175 °C (Table 3, entry 1) [44]. This method is scarcely used but is of interest when using primary 
or secondary amines [30]. The use of 2 equivalents of amine relative to the hydroximic acid causes a 
fast dehydrohalogenation followed by a nucleophilic attack of the amine on the intermediate nitrile 
oxide (Table 3, entry 2) [30]. 
Table 3. Reaction of ammonia and amines with oximinoethers and hydroximic acid chlorides. 
Entry Ammonia and Amine Action on  
1 oximinoether O
N
OH
NH3
NH2
N
OH
C2H5OH
2 hydroximic acid chlorides 
NH3
Cl
N
NH2
N
OHOH
2 thioamide
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The second synthetic process allowing the preparation of amidoximes involves the reaction of 
ammonia or amines with oximinoethers, hydroximic acids or nitric oxides (Table 3) [7,30]. The first 
example described in the literature is the reaction of ammonia with ethyl benzhydroximic acid for 8 
h at 175 °C (Table 3, entry 1) [44]. This method is scarcely used but is of interest when using primary 
or secondary amines [30]. The use of 2 equivalents of amine relative to the hydroximic acid causes a 
fast dehydrohalogenation followed by a nucleophilic attack of the amine on the intermediate nitrile 
oxide (Table 3, entry 2) [30]. 
Table 3. Reaction of ammonia and amines with oximinoethers and hydroximic acid chlorides. 
Entry Ammonia and Amine Action on  
1 oximinoether O
N
OH
NH3
NH2
N
OH
C2H5OH
2 hydroximic acid chlorides 
NH3
Cl
N
NH2
N
OHOH
3 amidine hydrochloride orhydrazide imide
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The second synthetic process allowing the preparation of amidoximes involves the reaction of 
am onia or amines with oximinoethers, hydroximic acids or nitric oxides (Table 3) [7,30]. The first 
example described in the literature is the reaction of ammonia with ethyl benzhydroximic acid for 8 
h at 175 °C (Table 3, entry 1) [44]. This method is scarcely used but is of interest when using primary 
or secondary amines [30]. The use of 2 equivalents of amine relative to the hydroximic acid causes a 
fast dehydrohalogenation followed by a nucleophilic attack of the amine on the intermediate nitrile 
oxide (Table 3, entry 2) [30]. 
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The second synthetic process allowing the preparation of amidoximes involves the reaction of 
am onia or amines with oximinoethers, hydroximic acids or nitric oxides (Table 3) [7,30]. The first 
example described in the literature is the reaction of ammonia with ethyl benzhydroximic acid for 8 
h at 175 °C (Table 3, entry 1) [44]. This method is scarcely used but is of interest when using primary 
or secondary amines [30]. The use of 2 equivalents of amine relative to the hydroximic acid causes a 
fast dehydrohalogenation followed by a nucleophilic attack of the amine on the intermediate nitrile 
oxide (Table 3, entry 2) [30]. 
Table 3. Reaction of ammonia and amines with oximinoethers and hydroximic acid chlorides. 
Entry Ammonia and Amine Action on  
1 oximinoether
N
OH
NH3
N 2
N
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2 hydroximic acid chlorides 
NH3
Cl
N
N 2
N
OHOH
5 Imidoylbenzo-triazole
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The second synthetic process allowing the preparation of amidoximes involves the reaction of 
am onia or amines with oximinoethers, hydroximic acids or nitric oxides (Table 3) [7,30]. The first 
example described in the literature is the reaction of ammonia with ethyl benzhydroximic acid for 8 
h at 175 °C (Table 3, entry 1) [44]. This method is scarcely used but is of interest when using primary 
or secondary amines [30]. The use of 2 equivalents of amine relative to the hydroximic acid causes a 
fast dehydrohalogenation followed by a nucleophilic attack of the amine on the intermediate nitrile 
oxide (Table 3, entry 2) [30]. 
Table 3. Reaction of ammonia and amines with oximinoethers and hydroximic acid chlorides. 
Entry Ammonia and Amin  Action on  
1 oximinoether
N
OH
NH3
N 2
N
OH
C2H5OH
2 hydroximic acid chlorides 
NH3
Cl
N
N 2
N
OHOH
6
Open chain pyrazine
derivatives and/or
pyrrolopyrazin
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The second synthetic process allowing the preparation of amidoximes involv s the reaction of 
am onia or amines with oximinoethers, hydroximic cids or nitric oxides (Table 3) [7,30]. The first 
example escribed in the literature is the reaction of ammonia with ethyl benzhydroximic cid for 8 
h at 175 °C (Table 3, entry 1) [44]. This method is scarcely used but is of interest when using primary 
or secondary amines [30]. The use of 2 equivalents of amine relative to the hydroximic acid causes a 
fast dehydrohalogenation followed by  nucleop ilic attack of the amine on the interme iate nitrile 
oxide (Table 3, entry 2) [30]. 
Table 3. Reaction of ammonia and amines with oximinoethers and hydroximic acid chlorides. 
Entry Ammonia and Amine Action on  
1 oximinoether
N
OH
NH3
N 2
N
OH
C2H5OH
2 hydroximic acid chlorides 
NH3
Cl
N
N 2
N
OHOH
The us of the nitriles and hydroxylamine allows usually to obtain th expected amidoximes
in go d yields in a r action tim varying from of 1 to 48 h depending on the substrates. It s the
leading method to prepare amidoximes using readily av il ble nitril s as starting substrates [36–38].
Hydroxylamine ydrochloride is a sociat d to base like riethylamine or sodium carbonate (2 o 6
equiv lents) that allow the n situ ge er tion of hydroxyla in . The a dition of ydroxylam n can b
conducted at room temperature but is usually p rformed in refluxing ethan l or methan l to decrease
the reaction ti e [36,37]. Aromatic amidoximes are obtained in higher yields than aliphatic ones.
Nevertheless, it is still possible to impr ve the yield by adding an excess of hydroxylamine.
The use of a aqueous solution of hydroxylamine has also been reported. In this case,
a base is not required and the reaction time is generally shorter than when using hydroxylamine
hydrochloride [38,39]. This method has been demonstrated to be of interest for the efficient preparation
of amidoximes starting from aliphatic nitriles.
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Recently, Ranjbar-Karimi et al. synthesized a series of amidoximes using hydroxylamine and
nitriles via a solvent free method under ultrasonic irradiation. The reaction proceeds in short time and
allows the production of amidoximes in high yields (70–85%) [40].
Finally, the ring-opening of heterocycles using hydroxylamine was also demonstrated to be
of interest for the preparation of amidoximes. One of the most recent methods was developed
by Katritzky et al. by using imidoylbenzotriazoles and hydroxylamine as starting reagents under
microwave irradiation (Table 2, entry 5). This method allows the fast preparation of amidoximes
(reaction time of 5–15 min) and in good yields (65–81%) [41]. Hydroxylamine was also used for the
synthesis of pyrazine-based amidoximes from open chain pyrazine derivatives or their pyrrolopyrazine
tautomers. The reaction was demonstrated to occur either via the attack of hydroxylamine on the
nitrile or the pyrrolidine ring. These reactions gave amidoximes in yields ranging from 63–93% after
18 h (Table 2, entry 6) [42,43].
The second synthetic process allowing the preparation of amidoximes involves the reaction of
ammonia or amines with oximinoethers, hydroximic acids or nitric oxides (Table 3) [7,30]. The first
example described in the literature is the reaction of ammonia with ethyl benzhydroximic acid for 8 h
at 175 ◦C (Table 3, entry 1) [44]. This method is scarcely used but is of interest when using primary or
secondary amines [30]. The use of 2 equivalents of amine relative to the hydroximic acid causes a fast
dehydrohalogenation followed by a nucleophilic attack of the amine on the intermediate nitrile oxide
(Table 3, entry 2) [30].
Table 3. Reaction of ammonia and amines with oximinoethers and hydroximic acid chlorides.
Entry Ammonia and Amine Action on Reaction
1 oximinoether
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The second synthetic process allowing the preparation of amidoxim s involves the reaction of 
a monia or amines with oximinoethers, hydroximic acids or nitric oxides (Table 3) [7,30]. The first 
example described in the literature is the reaction of ammonia with ethyl benzhydroximic acid for 8 
h at 175 °C (Table 3, entry 1) [44]. This method is scarcely used but is of interest when using primary 
or secondary amines [30]. The use of 2 equivalents of amine relative to the hydroximic acid causes a 
fast dehydrohalogenation followed by a nucleophilic attack of the amine on the intermediate nitrile 
oxide (Table 3, entry 2) [30]. 
Table 3. Reaction of ammonia and amines with oximinoethers and hydroximic acid chlorides. 
Entry Ammonia and Amine Action on  
1 oximinoether O
N
OH
NH3
NH2
N
OH
C2H5OH
2 hydroximic acid chlorides 
NH3
Cl
N
NH2
N
OHOH
2 hydroximic acid chlorides
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The second synthetic process allowing the preparation of amidoximes involves the reaction of 
ammonia or amines with oximinoethers, hydroximic acids or nitric oxides (Table 3) [7,30]. The first 
example described in the literature is the reaction of ammonia with ethyl benzhydroximic acid for 8 
h at 175 °C (Table 3, entry 1) [44]. This method is scarcely used but is of interest when using primary 
or secondary amines [30]. The use of 2 equivalents of amine relative to the hydroximic acid causes a 
fast dehydrohalogenation followed by a nucleophilic attack of the amine on the intermediate nitrile 
oxide (Table 3, entry 2) [30]. 
Table 3. Reaction of ammonia and amines with oximinoethers and hydroximic acid chlorides. 
Entry Ammonia and Amine Action on  
1 oximinoether O
N
OH
NH3
NH2
N
OH
C2H5OH
2 hydroximic acid chlorides 
NH3
Cl
N
NH2
N
OHOH
Table 4. Miscellaneous reactions allowing the preparation of amidoximes.
Entry Method Reaction
1
Reduction of nitrosolic
acids and related
compounds
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Some exampl s of reactions r rely described in the literature but allowing the p eparation of 
amidoximes are described in Table 4. The reduction of benzonitrosolic acid with hydrogen sulfide 
was reported in 1906 by Wieland and Bauer (entry 1) [45]. 
Some reducing agents are able to open nitrogen containing heterocycles like 1,2,4-oxadiazoles, 
Δ′-1,2,4-oxadiazoles, 1-alkoxyadenines and 1,2,5-oxadiazoles [7,30]. The reaction of lithium 
aluminum hydride (LiAlH4) with Δ′-1,2,4-oxadiazoles allows the break of the C-O bond to give N-
substituted amidoximes in 70% to 72% yield (entry 2) [46]. 
Finally, 1,2,4-oxadiazoles can also be transformed into amidoximes (yield of 75%–85%) by 
reaction with aqueous NaOH [47]. Amidoximes were obtained in lower yields (35%–63%) after 
passing 1-alkoxyadenine derivatives through Amberlite IRA 402 column and heating the eluate at 
30–40°C for 7–48 h [48]. 
Table 4. Miscellaneous reactions allowing the preparation of amidoximes. 
Entry Method
1 
Reduction of nitrosolic 
acids and related 
compounds 
N
N
OH
O
2H2S NH2
N
OH
H2O 2S
2 
Ring opening of nitrogen-
containing heterocycles 
N
ON LiAlH4
N
H
NOH
R2NO2
R1
R
R= COOEt, R1= Cl
R= COOEt, R1= NO2
R= NO2, R1= NO2
R2= (CH2)2NH2
R2= (CH2)2NH2
R2= Me
3.2. Synthesis of Oximes 
An oxime is a compound belonging to imines family (RR′C = NOH). If R is an alkyl or an aryl 
group, R′ may be a hydrogen atom (aldoxime) or an alkyl/aryl group (ketoxime) (Figure 1). These 
compounds are usually synthesized by the addition of hydroxylamine on an aldehyde or a ketone 
[25,49,50]. The preparation of oximes is extensively described in the literature. Some improvements 
were described to enhance the yields and decrease the by-products formation. In 1999, Hajipour et 
al. reported the oximation of aldehydes and ketones using hydroxylamine hydrochloride under 
microwave irradiation in solvent free conditions. The process was demonstrated to be of higher 
efficiency for the synthesis of aldoximes using hydroxylamine hydrochloride and silica gel (yields 
higher than 76% and reaction time of 4 min) [51]. A similar solvent free method was reported in 2002 
using hydroxylamine hydrochloride and zinc oxide giving yield of 80-98% and reaction time varying 
between 5 and 15 min at 140–170°C [52]. 
Recently, Li et al. reported an efficient synthesis of oximes under sonication (yields ranging 51 
to 99% and short reaction times). The reaction is conducted in ethanol in the presence of anhydrous 
sodium sulfate [53]. 
Oximes can also be synthesized by the oxidation of aliphatic amines using m-CPBA. This 
reaction gave very high yields (>90%) in 20 min and at room temperature [54]. 
4. Oxidation of Amidoximes/Oximes and NO Release
During many years, NO was considered to present no beneficial biological effects and to be even 
toxic due to its presence in polluted environments [55]. In the 1980s, it was observed that a molecule 
released from the endothelium is responsible of the vasodilators effects and it was later identified as 
NO. Since, numerous studies on NO showed many biological benefits including its important role in 
vasodilation and blood pressure reduction [56]. For this reason, amidoximes and oximes were 
studied for their capacity of NO release. 
4.1. Oxidation by Chemicals and Biomimetics 
2
Ring opening of
nitrogen-containing
heterocycles
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Some examples of reactions rarely described in the literature but allowing the preparation of 
amidoximes are described in Table 4. The reduction of benzonitrosolic acid with hydrogen sulfide 
was reported in 1906 by Wieland and Bauer (entry 1) [45]. 
Some reducing agents are able to open nitrogen containing heterocycles like 1,2,4-oxadiazoles, 
Δ′-1,2,4-oxadiazoles, 1-alkoxyadenines and 1,2,5-oxadiazoles [7,30]. The reaction of lithium 
aluminum hydride (LiAlH4) with Δ′-1,2,4-oxadiazoles allows the break of the C-O bond to give N-
substituted amidoximes in 70% to 72% yield (entry 2) [46]. 
Finally, 1,2,4-oxadi zoles can also be transformed into amidoximes (yield of 75%–85%) by 
reaction with aqueous NaOH [47]. Amidoximes were obtained in lower yields (35%–63%) after 
passing 1-alkoxyadenine derivatives through Amberlite IRA 402 column and heating the eluate at 
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3.2. Synthesis of Oximes 
An oxime is a compound belonging to imines family (RR′C = NOH). If R is an alkyl or an aryl 
group, R′ may be a hydrogen atom (aldoxime) or an alkyl/aryl group (ketoxime) (Figure 1). These 
compounds are usually synthesized by the addition of hydroxylamine on an aldehyde or a ketone 
[25,49,50]. The preparation of oximes is extensively described in the literature. Some improvements 
were described to enhance the yields and decrease the by-products formation. In 1999, Hajipour et 
al. reported the oximation of aldehydes and ketones using hydroxylamine hydrochloride under 
microwave irradiation in solvent free conditions. The process was demonstrated to be of higher 
efficiency for the synthesis of aldoximes using hydroxylamine hydrochloride and silica gel (yields 
higher than 76% and reaction time of 4 min) [51]. A similar solvent free method was reported in 2002 
using hydroxylamine hydrochloride and zinc oxide giving yield of 80-98% and reaction time varying 
between 5 and 15 min at 140–170°C [52]. 
Recently, Li et al. reported an efficient synthesis of oximes under sonication (yields ranging 51 
to 99% and short reaction times). The reaction is conducted in ethanol in the presence of anhydrous 
sodium sulfate [53]. 
Oximes can also be synthesized by the oxidation of aliphatic amines using m-CPBA. This 
reaction gave very high yields (>90%) in 20 min and at room temperature [54]. 
4. Oxidation of Amidoximes/Oximes and NO Release
During many years, NO was considered to present no beneficial biological effects and to be even 
toxic due to its presence in polluted environments [55]. In the 1980s, it was observed that a molecule 
released from the endothelium is responsible of the vasodilators effects and it was later identified as 
NO. Since, numerous studies on NO showed many biological benefits including its important role in 
vasodilation and blood pressure reduction [56]. For this reason, amidoximes and oximes were 
studied for their capacity of NO release. 
4.1. Oxidation by Chemicals and Biomimetics 
Some examples of reactions rarely described in the literature but allowing the preparation of
amidoximes are described in Table 4. The reducti n of benzonitrosolic acid with hydro en sulfide was
reported in 1906 by Wieland and Bauer (entry 1) [45].
Molecules 2019, 24, 2470 7 of 19
Some reducing agents are able to open nitrogen containing heterocycles like 1,2,4-oxadiazoles,
∆′-1,2,4-oxadiazoles, 1-alkoxyadenines and 1,2,5-oxadiazoles [7,30]. The reaction of lithium aluminum
hydride (LiAlH4) with ∆′-1,2,4-oxadiazoles allows the break of the C-O bond to give N-substituted
amidoximes in 70% to 72% yield (entry 2) [46].
Finally, 1,2,4-oxadiazoles can also be transformed into amidoximes (yield of 75–85%) by reaction
with aqueous NaOH [47]. Amidoximes were obtained in lower yields (35–63%) after passing
1-alkoxyadenine derivatives through Amberlite IRA 402 column and heating the eluate at 30–40◦C for
7–48 h [48].
3.2. Synthesis of Oximes
An oxime is a compound belonging to imines family (RR′C = NOH). If R is an alkyl or an aryl group,
R′ may be a hydrogen atom (aldoxime) or an alkyl/aryl group (ketoxime) (Figure 1). These compounds
are usually synthesized by the addition of hydroxylamine on an aldehyde or a ketone [25,49,50].
The preparation of oximes is extensively described in the literature. Some improvements were
described to enhance the yields and decrease the by-products formation. In 1999, Hajipour et al.
reported the oximation of aldehydes and ketones using hydroxylamine hydrochloride under microwave
irradiation in solvent free conditions. The process was demonstrated to be of higher efficiency for the
synthesis of aldoximes using hydroxylamine hydrochloride and silica gel (yields higher than 76% and
reaction time of 4 min) [51]. A similar solvent free method was reported in 2002 using hydroxylamine
hydrochloride and zinc oxide giving yield of 80-98% and reaction time varying between 5 and 15 min
at 140–170◦C [52].
Recently, Li et al. reported an efficient synthesis of oximes under sonication (yields ranging 51
to 99% and short reaction times). The reaction is conducted in ethanol in the presence of anhydrous
sodium sulfate [53].
Oximes can also be synthesized by the oxidation of aliphatic amines using m-CPBA. This reaction
gave very high yields (>90%) in 20 min and at room temperature [54].
4. Oxidation of Amidoximes/Oximes and NO Release
During many years, NO was considered to present no beneficial biological effects and to be even
toxic due to its presence in polluted environments [55]. In the 1980s, it was observed that a molecule
released from the endothelium is responsible of the vasodilators effects and it was later identified as
NO. Since, numerous studies on NO showed many biological benefits including its important role in
vasodilation and blood pressure reduction [56]. For this reason, amidoximes and oximes were studied
for their capacity of NO release.
4.1. Oxidation by Chemicals and Biomimetics
Since the NO production in the human body originates from the oxidation of l-arginine by NOS,
this oxidation route and the factors affecting the oxidation were investigated. In 1998, Koikov et al.
studied the oxidation of three series of compounds including oximes and amidoximes at a concentration
of 2 × 10−4 M with K3Fe[(CN)6] at pH 12 [57]. Under these conditions, oximes were not able of releasing
NO and this phenomenon was explained by the acceptor or donor properties of the substituents
(hydroxyphenyl and pyridine rings) and by the acidity of the oxime functions. However, many tested
amidoximes showed the capacity to release NO in the presence of K3Fe[(CN)6] and methyl and phenyl
amidoximes released 25% and 10% of NO, respectively. It was observed that replacing the phenyl ring
by a pyridine ring allows to increase twice the amount of released NO and that the amidoximes exhibit
quite a similar potential of NO release than methylamidoxime. The structures of these amidoximes are
shown in Figure 6. The most important release was observed for the pyridine-2,6-diamidoxime for
which the amount of released NO reached up to 40%. Benzonitrile was also identified as the major
product present after the oxidation of benzamidoxime.
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To better understand the products formed during the oxidation of amidoximes, Vadon-Le Goff
et al. reported the use of various oxidants and biomimetic systems to study the reaction products as
well as the causes and factors affecting the outcome of the reaction [4]. The authors evaluated the
potential of NO release of 4-chlorobenzamidoxime in the presence of different oxidants. Amides or
nitriles were identified as the main products but the presence of a dimeric product in the mixture was
also detected (Figure 7).
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It was demonstrated that with oxidants like Pb(OAc)4 and Ag2CO3, amidoximes are selectively
oxidized into nitriles, while amides were selectively formed using oxidants capable of transferring one
oxygen atom like H2O2, t-BuOOH or m-CPBA. Using m-CPBA, 4-chlorobenzamidoxime was oxidized
into a mixture of dimeric products and amide, the latter being the major component. This oxidant,
as well as t-BuOOH, associated with catalytic amounts of iron-porphyrin generates preferentially the
nitrile in less than 1 h (ca. 80% of the amidoxime oxidized) (Table 5, lines 1–3). This likely originates
from the formation of highly reactive iron-oxo species which oxidize the amidoxime into the nitrile.
This result is in accordance with those described in the literature related to the oxidation of amidoximes
by hemoproteins. Horseradish peroxidase, able of generating iron-oxo species in the presence of H2O2,
oxidizes amidoximes to nitriles and a dimeric product. On the other hand, the oxidation by CYP450
generates exclusively the amide product instead of the nitrile. This was explained by the presence of
the superoxide O2•− radical anion or of a protein-metal-O2 complex instead of the presence of the
iron-oxo intermediates (see Section 4.2 for the oxidation by CYP450).
Table 5. Summary of the major oxidation products after amidoxime reaction with different chemical
and biomimetic oxidants.
Major Oxidation Products
Entry Amide Nitrile
1 Monoelectronic oxidants
√
2 O2 atom donors
√
3 O2 atom donors + iron-porphyrin catalyst
√
4 Photooxygenation of amidoximates
√
5 IBX
√
6 IBX/TEAB
√
√
Major product formed.
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Amidoximes and oximes can also be oxidized via the amidoximate/oximate anions in the presence
of singlet oxygen [58]. The authors demonstrate that amidoximes and oximes are inert to 1O2 but
once converted to amidoximates and under photooxygenation, amidoximes can be oxidized into the
corresponding amides along with nitriles as minor products (Table 5, entry 4). The use of 1O2 is similar
to the oxidation of N-hydroxyguanidines by the NOS and clarifies the biological oxidation routes
(Figure 8, red part).
To better understand the oxidation process of amidoximes, oxidants like 2-iodobenzoic acid (IBX)
and the IBX/tetraethylammonium bromide (TEAB) combination were also used [12]. The authors
demonstrate that IBX can selectively oxidize benzamidoxime (Figure 8, blue part) into amide (best
yield of 83% using an amidoxime:IBX ratio of 1:1 and only 10% of the nitrile). This method was
extended to various amidoximes and similar results were obtained. Nevertheless, the use of an
amidoxime:IBX:TEAB molar ratio of 1:2:2 gave 90% of the nitrile and only 5% of the amide. By using
this ratio with a series of amidoximes, similar results were obtained by the authors (Table 5, entries 5
and 6).
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4.2. Biological Pathways of Amidoximes and Oximes Oxidation
As it is well known, NO is synthesized in vivo by the NOS enzymes. In recent years, many scientists
got interested in finding new ways to oxidize amidoximes and oximes in order to increase the NO
concentration in the organism. A few studies demonstrated that C=N-OH moieties present in
compounds like amidoximes and oximes can be oxidized by CYP450 enzymes [59,60]. In 1998, a study
showed the key role of CYP450 in the oxidation of amidoximes, oximes and N-hydroxyguanidines
along with their oxidation products [5]. In the presence of rat liver microsomes, NADPH and O2,
amidoximes and oximes can be oxidized and release NO and NO-related aerobic products like NO2–
and NO3−. The presence of both NADPH and O2 and of the active microsomes was demonstrated
to be essential for the oxidation, indicating that this reaction is enzymatic. Moreover, the authors
demonstrated that the CYP450 present in the microsomes are responsible for this reaction by using
either the CYP450 inhibitor Miconazole which caused the inhibition by ca. 80–90% of the reaction or
Dexomethasone (DEX), a CYP450 inducer, treated microsomes. The oxidation of various amidoximes
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and oximes generates both NO2− and NO3−, especially in the presence of DEX-treated microsomes
which boosts the oxidation. This release was always accompanied by the formation of amides and
nitriles in the case of amidoximes and of ketones and nitroalkanes in the case of ketoximes.
In 2004, another study used CYP450 to test the oxidation of the oximes. Hence, Mäntylä et al.
incubated buparvaquone–oxime and its derivatives with NADPH and either untreated rat liver
microsomes or treated ones with various CYP450 inducers. These buparvaquone’s prodrugs were
studied for their ability to be oxidized and releasing the corresponding buparvaquone alongside
NO which was quantified via the NO2- species produced [61]. All of the oximes were able to be
oxidized in the presence of CYP450 and release buparvaquone bearing a C=O function effective against
leishmaniasis. The presence of NO was also believed to have a role against this disease. The solubility
of the oximes prodrugs was further improved by the synthesis of their corresponding phosphate
prodrugs. These latter were able to release the corresponding oximes-buparvaquone [62].
Recently, we evaluated the capacity of mono- and bis-amidoximes to release NO by a
CYP450-mediated oxidation (Figure 9) [38]. Amidoximes were also incubated with NADPH and
untreated microsomes. Only aromatic mono-amidoximes showed an important NO release while the
aliphatic mono-amidoxime and the bis-amidoxime bearing both an aromatic and aliphatic amidoxime
released only small NO quantities. The inadequate size or shape of the latter compounds and/or the
lower reactivity of the aliphatic amidoximes compared to aromatic ones hinders their metabolization
by rat liver microsomes. It was of interest to determine if these amidoximes are able to release NO
once incubated with human cells not originating from the liver. For that purpose, these compounds
were first demonstrated to be cytocompatible with human vascular smooth muscle cells (HVSMC) and
were later incubated with these cells for 1 h to evaluate their ability to release NO. This test showed
that all of the amidoximes are able to release NO and to increase the NO storage through nitrosothiol
(RSNO) formation inside the cells. It is worth mentioning that the bis-amidoxime exhibited a high
potential for the generation of RSNO, very close to that of the aromatic mono-amidoximes, but at a
twice lower concentration.
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Other reports focused on finding the capacity of the NOS in oxidizing amidoximes and oximes.
Acetoxime can be oxidized by CYP450 and NADPH in the presence of metal complexes into NO2– and
reactive NO species [63]. However, this study clearly proved that acetoxime cannot be oxidized by the
NOS II enzyme and cannot even inhibit its activity, which suggests a low affinity between NOS and
this ketoxime. This demonstrates that the oxidation pathway of acetoxime in the cells involves only
CYP450. In another study, four amidoximes were incubated with NOS I and II and NADPH and the NO
formation was monitored by the Griess assay in order to study the amidoximes recognition by NOS [64].
All the amidoximes were inactive in the presence of NOS and did not show any NO release. Moreover,
they are also very bad inhibitors of NOS I and II. The corresponding N-hydroxyguanidines analogs
showed high affinity, indicating that the NOS better recognizes molecules bearing the –NH-C(R)=NH
moiety than C=NOH. The latest study related to that topic was conducted in 2002 [65], and a series
of N-hydroxyguanidines, amidoximes, ketoximes and aldoximes where tested for their NO release
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capacity in the presence of recombinant NOS II. The presence of an unmodified N-hydroxyguanidine
function is mandatory for the oxidation by the NOS. Thus, none of the amidoximes and oximes could
be oxidized by this enzyme.
As shown by these studies, CYP450 seems to be responsible of the oxidation of both amidoximes and
oximes while NOS does not appear to have a role in these oxidations. As mentioned above, the oxidations
by CYP450 afforded as major products amides in the case of amidoximes and ketones in the case of
oximes alongside with the release of NO, nitrites and nitrates [63–65]. The mechanism of amidoximes
and oximes oxidation by CYP450 that generates amides/ketones is explained by the formation of the
superoxide radical anion (O2•−) which is a dissociation product of the CYP450-Fe(II)-O2 complex,
this latter was shown to be easily transformed to CYP420-Fe(II)-O2 during the oxidation [60,63–65].
The formation, even in small amounts, of a nitrile and nitroalkane mixture originates from the presence
of an iron-oxo complex as it is the case for the biomimetic reactions generating nitriles. Many CYP450
isoforms have been identified as responsible of the oxidations of these products like CYP4501A1,
CYP4502B1, and CYP4502E1 [5,63].
These results demonstrate that NOS are not optimal for the evaluation of the NO release from
amidoximes. It is preferable to use the CYP450 pathway that shows good results with both amidoxime
and oxime functions.
4.3. In Vivo and In Vitro Biological Responses to NO Release from Amidoximes/Oximes Oxidation
Along with the discovery of the capacity of amidoximes and oximes to release NO in the presence
of biological extracts and cells, many scientists started to test these products on biological tissues.
Indeed, the in vivo generation of NO has gained a lot of attention among others due its capacity of
vasodilatation and thus reducing platelet aggregation and thrombosis formation.
The first major works that appeared on that topic were published by Rehse et al. in 1997 and
1998 [66,67]. Seven aryl azoamidoximes and their effects on thrombosis inhibition, blood pressure
and inhibition of platelet aggregation were investigated [66]. Five of the seven amidoximes inhibited
the formation of thrombus in mesenteric rat vessels and even two of these amidoximes inhibited
the thrombus formation by more than 20% (Figure 10). The remaining two amidoximes bearing a
methoxy or a fluoro group on the para position did not show any significant effect on the thrombus
formation in both arterioles and venules. The inactive 4-methoxyphenylazo-methanamidoxime had
also no significant action in lowering the blood pressure during 2, 4, 6, and 24 h. The highly active
4-chlorophenylazo-methanamidoxime decreased the blood pressure for 24 h with a maximum efficiency
of 16% ± 10% at 6 h. It is noteworthy that both amidoximes were able to release NO in the presence
of DEX-treated rat liver microsomes and NADPH, but only the second amidoxime was used by the
cells in order to lower blood pressure and reduce thrombi formation. The last test conducted with
these amidoximes was the platelet aggregation. All of the studied amidoximes exhibited low or poor
activity after calculating their IC50 following the Born test. This means that these amidoximes are not
able of being oxidized in these conditions.
In another series of experiments, 17 compounds containing different aliphatic, aromatic,
and bis-amidoximes were tested [67]. The results were in accordance with the previous study
since the majority of the amidoximes showed a poor effect or even a lack of activity towards the
inhibition of platelet aggregation which proves once more that the platelet rich plasma is not convenient
for amidoximes oxidation. The most effective amidoxime was the aromatic one bearing a chlorine atom
on the para position and an ethene group between the phenyl and the amidoxime function. The presence
of this ethene group raised the efficiency for the platelet aggregation inhibition. Bis-amidoximes
displayed a good activity for the inhibition of thrombus formation in arterioles and venules and the
bis-amidoxime bearing an ethene group exhibited the highest percentage of thrombus inhibition.
All other amidoximes also show some activity and it was noticed that adding a group on the para
position may increase the thrombi formation inhibition, the key parameter being the lipophilicity
rather than the electronic variations. The amidoximes exhibiting the highest activity in reducing the
Molecules 2019, 24, 2470 12 of 19
thrombus formation were also tested for decreasing the blood pressure but their activity was weak
(the highest effect was observed for the bis-amidoxime with a blood pressure lowering of only 5%)
(Figure 10).
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These studies were not limited to amidoximes but also to azide oximes. These compounds showed
better antiplatelet effect than the azide amidoximes and the amidoximes since the majority of the
studied azide oximes exhibited a capacity to inhibit platelet aggregation with the oxime bearing the
nitrophenyl function having an IC50 of 2 µmol/L in the Born test [68]. Similarly to amidoximes, the
electronic variance and the lipophilicity had no major role in changing the efficiency of the oximes,
however strong electron withdrawing groups like a nitro function seem to increase the oxime activity.
All of the oximes showed also 10–20% efficiency in thrombus formation inhibition and two of them
exhibited values higher than 20%. Additionally, azide oximes allowed a decrease of the blood pressure
that may reach 10–15%. This parameter is not connected to the thrombus formation inhibition since the
compound exhibiting the highest antithrombotic activity did not have the highest capacity of blood
pressure lowering. Overall, the azide oximes showed to be more effective than the azide amidoximes
and other studied amidoximes (Figure 10).
In another study and in order to evaluate the relaxation capacity of amidoximes, Jia et al. used
formamidoxime in the presence of a tracheal ring previously contracted by carbachol, a cholinomimetic
drug. They observed a relaxation effect on the tracheal ring after the incubation along with an
accumulation of the cyclic guanosine 3′,5′-monophosphate (cGMP) level after incubation with the
tracheal smooth muscle cells [69]. The relation between the production of cGMP and the relaxation
of the ring was proved by using a cGMP inhibitor on both the tracheal rings and the smooth muscle
cells. This inhibitor prevented the relaxation of the rings and the formation of the cGMP in both
cultures. After the detection of NO in the incubation media of the tracheal smooth muscle cells
with formamidoxime, the authors proposed that after the amidoxime oxidation, the released NO
activates the formation of the cGMP which induces the relaxation of the tracheal ring. As previously,
a NOS inhibitor was used with the cultured cells and the tracheal rings but it did not inhibit the
production of cGMP or the relaxation of the rings. On the contrary, the cGMP production and the
ring relaxation were both inhibited after the use of a CYP450 inhibitor, 7-ethoxyresorufin. Similarly,
the cGMP production was inhibited after the use of Miconazole on the cell cultures. These results
provided evidence that the pathway of the amidoxime oxidation in the tracheal smooth muscle cells
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and tracheal ring is through CYP450 and not NOS, and more specifically by CYP4501A1 being a strong
substrate of the 7-ethoxyresorufin.
This study using formamidoxime got a lot of attention and other researches were conducted to see
if this compound, along with other amidoximes and oximes, exhibited the same effects in the rat aorta.
Vetrovsky et al. tested a series of amidoximes and one oxime in the presence of endothelium-denuded
rat aorta (Figure 11) [70]. All of the compounds caused an endothelium-independent relaxation
higher than the NOHA with 4-chlorobenzamidoxime being the most active. It should also be noted
that formamidoxime (Table 6, entry 1, in vitro studies) caused an important rat aorta relaxation
close to that of the 4-chlorobenzamidoxime. The authors demonstrate that the presence of
electron donating or withdrawing groups has a limited influence on the aorta relaxation since
benzamidoxime, 4-methoxybenzamidoxime, and 4-n-(hexyloxy)benzamidoxime were slightly less
potent than 4-chlorobenzamidoxime and 4-nitrobenzamidoxime. Additionally, the lipophilicity increase
in 4-n-(hexyloxy)benzamidoxime compared to 4-methoxybenzamidoxime did not play a key role on
the relaxation effect. Finally, the use of an oxime instead of an amidoxime function caused a decrease
in the relaxation capacity.
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(Table 6, entries 2–4, in vitro studies), it was shown that all of these oximes are more potent to induce 
relaxation in rat aorta than hydroxyguanidine, formaldoxime being the most potent [71]. Similar to 
amidoximes, the lipophilicity increase from acetaldoxime to acetoxime does not significantly affect 
the induced relaxation. For the previously studied amidoximes and oximes, cGMP and NO were 
involved in the aorta relaxation since the addition of the guanylate cyclase inhibitor and NO-
scavengers completely inhibited the relaxation. The use of NOS inhibitors and CYP450 inhibitors like 
proadifen did not alter the relaxation effect, indicating that other oxidation pathways are involved 
with these amidoximes and oximes. However, the use of the 7-ethoxyresorufin inhibited the 
relaxation of the aorta rings in the presence of 4-chlorobenzamidoxime and oximes but the authors 
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vitro studies, the three tested oximes and the formamidoxime caused an aorta relaxation, 
contrariwise, in vivo only formamidoxime and formaldoxime were capable of lowering the blood 
pressure, with the amidoxime being the most active. This result was different from the in vitro 
experiments where the formaldoxime was the most potent. The inhibition of the guanylate cyclase in 
vivo caused the inhibition of the blood pressure reduction when using formaldoxime, which indicates 
that NO is responsible for the whole effect while with formamidoxime NO is responsible for one third 
of the effect, suggesting that with the amidoxime not the whole blood pressure decrease is caused by 
the NO release. Finally, hydrophilic substances were found to be more active in vivo than in vitro. 
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Using the same tests but focusing on oximes like acetaldoxime, acetoxime and formaldoxime
(Table 6, entries 2–4, in vitro studies), it was shown that all of these oximes are more potent to induce
relaxation in rat aorta than hydroxyguanidine, formaldoxime being the most potent [71]. Similar to
amidoximes, the lipophilicity increase from acetaldoxime to acetoxime does not significantly affect
the induced relaxation. For the previously studied amidoximes and oximes, cGMP and NO were
involved in the aorta relaxation since the addition of the guanylate cyclase inhibitor and NO-scavengers
completely inhibited the relaxation. The use of NOS inhibitors and CYP450 inhibitors like proadifen
did not alter the relaxation effect, indicating that other oxidation pathways are involved with these
amidoximes and oximes. However, the use of the 7-ethoxyresorufin inhibited the relaxation of the
aorta rings in the presence of 4-chlorobenzamidoxime and oximes but the authors suggested that this
is not due to an inhibition of the CYP4501A1 but to an inhibition of a different NADPH-dependent
reductase pathway. In a following study [6], the aliphatic oximes and formamidoxime (Table 6) were
tested in vivo to evaluate the blood pressure decrease in conscious chronically cannulated rats in which
the endogenous NO synthesis was blocked. In the precedent in vitro studies, the three tested oximes
and the formamidoxime caused an aorta relaxation, contrariwise, in vivo only formamidoxime and
formaldoxime were capable of lowering the blood pressure, with the amidoxime being the most active.
This result was different from the in vitro experiments where the formaldoxime was the most potent.
The inhibition of the guanylate cyclase in vivo caused the inhibition of the blood pressure reduction
when using formaldoxime, which indicates that NO is responsible for the whole effect while with
formamidoxime NO is responsible for one third of the effect, suggesting that with the amidoxime not
the whole blood pressure decrease is caused by the NO release. Finally, hydrophilic substances were
found to be more active in vivo than in vitro.
More recently, other studies evaluated the potency of some oximes to induce a vasorelaxation in
superior mesenteric arteries isolated from rats. It was demonstrated that E-cinnamaldehyde oxime
was the most potent and able of causing a NOS and endothelium-independent vasorelaxation. The NO
release and relaxation activity of this compound were only partially inhibited by 7-ethoxyresorufin,
a CYP4501A1 specific inhibitor, but not by other CYP450 nonspecific inhibitor, which shows also
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that the oxime oxidation is catalysed by a NADPH-dependent reductase pathway in the superior
mesenteric arteries just like the studies in rat aortic rings. The relaxation pathway is also caused by
the activation of cGMP with a key role played by a type of K+ channel and the reduction of the Ca2+
influx [72]. The role of the K+ channels was demonstrated in another study published in 2014 after
the incubation of an oxime with rat aortic rings in the presence of different channel blockers [73].
The relaxation was observed when the enzyme and the aortic rings were incubated without the channel
blockers. Furthermore, when administered to conscious rats, the oxime caused the reduction of blood
pressure. The aorta and superior mesenteric artery rings relaxations were similar in the presence and
in the absence of the endothelium after the incubation with the oxime, indicating that NOS were not
responsible of the oxidation. The relaxation, as for the previously studied compounds, is achieved by
the release of NO and the activation of the cGMP pathway alongside the activation of the K+ channels.
Table 6. Comparison of some studied amidoximes and oximes for their aorta relaxation and pressure
decrease abilities.
Molecule In Vitro Rat Aorta Relaxation In Vivo Blood Pressure Decrease
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channels. 
In addition, amidoximes can also be used for their capacity of lowering the 
intraocular pressure (IOP) in rabbits due to the NO release followed by the formation of 
cGMP [74,75]. In 2006, Oresmaa et al. tested various imidazole amidoximes for their 
IOP-lowering abilities. Two of them (Figure 12) were able to produce NO and increase 
the cGMP formation when incubated with porcine iris-ciliary bodies but only the 
methyl form was able to reduce the IOP when administered intravitreally in rabbits. 
The esterification of the active amidoximes caused the loss of their biological activity. Figure 12. Imidazole amidoximes able to increase cGMP formation. 
All of these studies demonstrate that when amidoximes or oximes are incubated with cultured 
cells such as tracheal smooth muscle cells [69] or with biological tissues such as aortic/tracheal rings 
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[73]. The relaxation was observed when the enzyme and the aortic rings were incubated without the 
channel blockers. Furthermore, when administered to conscious rats, the oxime caused the reduction 
of blood pressure. The aorta and superior mesenteric artery rings relaxations were similar in the 
presence and in the absence of the endothelium after the incubation with the oxime, indicating that 
NOS were not responsible of the oxidation. The relaxation, as for the previously studied compounds, 
is achieved by the release of NO and the i ation of the cGMP pathway alongside the activation of 
the K+ channels. 
In addition, amidoximes can als  be used for thei  c pacity of lowering the intraocular pressure 
(IOP) in abbits due t  th  NO release followed by the formation of cGMP [74,75]. In 2006, Oresmaa 
et al. teste  various im dazole amidoxi es for their IOP-lowering abilit es. Two of them (Figure 12) 
were able to produce NO nd incr ase th cGMP for ation when ncubated with porcine ris-cili ry 
bodies but only the methyl for  was ble to reduce t IOP wh n administ red intravitreall  in 
rabbits. The esterificati n of the active amidoximes caused he loss of their biological activity. 
 
Figur  12. Imida ole amidoxim s ble to increase cGMP formation. 
All of these studies demonstrate that when amidoximes or oximes are incubated wit  cultured 
cells such as tracheal smooth uscle cells [69] or with biol gical tiss es such as aortic/tra heal rings 
. f r ti .
ll of these stu ies d monstrate that when amid ximes or oximes are incubated with cultured cells
such as tracheal smooth muscle cells [69] or with biological tissues such as ortic/tracheal rings [69,70],
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the generation of NO followed by the relaxation of the tissues is observed. This relaxation was proved
to be caused by an increase in the cGMP accumulation after the activation of the guanylate cyclase by
the released NO. Moreover, even in biological tissues, the NOS pathway does not seem to play a role
in the oxidation of these products [69–71]. However, in some biological tissues like aortic rings and
superior mesenteric arteries, CYP450 did not seem to play a role in the oxidation but it was suggested to
be another NADPH-dependent reductase pathway [70–72]. Independently from the enzyme involved
in the oxidation of amidoximes and oximes, it is now well established that the related NO release
causes an activation of the guanylate cyclase with an accumulation of cGMP. This is followed by an
activation of the BKCa channels which causes an efflux of the potassium ions and thus a decrease in the
calcium channels activity [72,73]. This pathway causes a relaxation in the targeted tissue along the
detected effects such as blood pressure decrease.
5. Conclusions
Amidoximes and oximes are compounds that are easy to synthesize and that present many
benefits especially in biological pathways. In this review, we focused on their NO donor abilities.
Many oximes and amidoximes can be oxidized by the CYP450 route rather than the NOS pathway
which is of high interest when the patient’s NOS is not functional. Additionally, these compounds
showed in vitro and in vivo abilities to cause the relaxation of aortas, to inhibit platelet aggregation
and to decrease the hypertension. For all these reasons, amidoximes and oximes are of high potential
for future use against many cardiovascular diseases.
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